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18,000 women die due to metastatic breast cancer in Germany per year. Median survival is 20–28 months after diagnosis.
The question we wanted to answer was whether survival has improved in routine care? For this purpose we conducted a
retrospective analysis of all patients with metastatic breast cancer who were treated between 06/1995-06/2013 in a
community-based oncology group practice in Germany. 716 patients were analyzed with a median age of 61
(31–93). Localizations of metastases were distributed as follows: 47% visceral, 36% bone, 9% lymphatic, 4% CNS,
4% others. 79% were hormone-receptor-positive, 20% Her2-positive, 9% triple-negative. Median overall survival
was 34 months (95% Confidence Interval: 31–37), median disease-specific survival 36.8 months and disease-specific
survival after 5 years 34%. Survival was significantly correlated with localizations of metastases, number of metastasized
organs, disease free survival since initial diagnosis, hormone-receptor status and age. Patients with hormone-receptor-
positive tumors had a median overall survival of 37 months, Her2-positive patients of 34 months and triple-negative
patients of 13 months. 86% of hormone-receptor-positive patients received antihormonal therapy. 81% of Her2-positive
patients received anti-Her2 therapy. In summary, longer survival is strongly restricted to hormone receptor- and Her2-
positive tumors most likely due to targeted therapies directed against the estrogen-receptor and Her2.
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Metastatic breast cancer is the tumor with the highest
mortality in women. In Germany about 18,000 women
die from breast cancer annually (Statistisches Bundesamt
https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/
Gesundheit/Todesursachen/Tabellen/SterbefaelleInsgesamt.
html). The median survival after initial diagnosis is 20–
28 months (Mauri et al. 2008; Gennari et al. 2005;
Giordano et al. 2004; Chia et al. 2007; Tai et al. 2004;
Dafni et al. 2010; Tevaarwerk et al. 2013; Allemani et al.
2013). The probability to be alive 5 years after initial
diagnosis of metastasis is according to tumor registry
data from Germany, England and the USA only 13-27%
(Tumorregister München http://www.tumorregister-muenchen.
de/facts/surv/surv_C50f_G.pdf; Holleczek et al. 2011;* Correspondence: weide@onkologie-koblenz.de
1Praxisklinik für Hämatologie und Onkologie, Neverstr. 5, 56068 Koblenz,
Germany
Full list of author information is available at the end of the article
© 2014 Weide et al.; licensee Springer. This is a
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in any medium, provided the original work is pWeide et al. 2012; Office for National Statistics (ONS)
http://www.ons.gov.uk/ons/publications/re-reference-
tables.html?edition=tcm%3A77-241176; Surveillance,
Epidemiology and End Results Program (SEER 18, 2004–
2010) http://seer.cancer.gov/statfacts/html/breast.html#
survival). During the last 18 years advances in targeted
therapy have been described in hormone-receptor and
Her2-positive tumors, which have resulted in prospect-
ive trials in longer survival. With regard to hormone-
receptor-positive tumors the introduction of aromatase
inhibitors, the antiestrogen fulvestrant and the mTOR
inhibitor everolimus has to be mentioned (Montemurro
et al. 2012). The discovery of Her2 as a negative prog-
nostic factor and the associated development of trastu-
zumab and other anti-Her2 therapies have led in studies
to a significant improvement in survival of these patients
(Murphy & Morris 2012). Tumor registry data from the
Saarland and from Munich imply that the survival of pa-
tients with metastatic breast cancer has not improved inn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Schlesinger-Raab et al. 2005). Contradictory publications
are available from other tumor registries and other institu-
tions that describe a survival improvement in routine care
(Mauri et al. 2008; Gennari et al. 2005; Giordano et al.
2004; Chia et al. 2007; Tai et al. 2004; Dafni et al. 2010;
Allemani et al. 2013; Weide et al. 2009). This improve-
ment in survival is causally attributed by the authors to the
introduction of new drugs (cytostatic agents, antihormonal
therapy and anti-Her2 therapies) (Mauri et al. 2008;
Gennari et al. 2005; Giordano et al. 2004; Chia et al. 2007;
Dafni et al. 2010; Allemani et al. 2013; Weide et al. 2009).
The objective of the present study was to find out
whether survival of unselected patients with metastatic
breast cancer has improved in routine care and if survival
differences can be detected?
Patients and methods
Retrospective analysis of all patients with metastatic breast
cancer who were treated between 06/1995-06/2013 in an
oncology group practice (Praxisklinik für Hämatologie
und Onkologie Koblenz, Germany). All relevant data were
transferred from patient files into a database and statisti-
cally analyzed using SPSS 19 and SURVSOFT.
At initial diagnosis the following data, among others, were
collected: TNM staging, estrogen- and progesterone-
receptor status, Her2 status (positively defined as IHC 3+
or IHC 2+ and CISH/FISH-positive) and adjuvant therapy.
At the time of metastasis was captured: time from initial
diagnosis to metastasis, age, estrogen- and progesterone-
receptor status, Her2 status, menopausal status, comorbid-
ities (Charlson Score), metastatic sites, number of involved
organs, palliative therapies, hospitalizations, causes and
places of death and overall survival (time from initial diag-
nosis of metastasis to death or end of observation).
Multivariate and univariate survival analyses were con-
ducted. First of all patients were classified according to
metastatic sites at initial diagnosis as follows: CNS affec-
tion, visceral metastasis without CNS affection, regional
metastasis of the lymph nodes, bone only metastasis and
localizations which could not be classified in this scheme.
For each group a median survival was calculated with the
help of the Kaplan-Meier method and differences in sur-
vival were tested for statistical significance by log-rank-
tests. Analyses concerning receptor status were carried
out analogically. Patients were either Her2-positive or/and
hormone-receptor positive or triple-negative.
The following potential parameters were dichotomized
tested in univariate Kaplan-Meier analyses and log-rank
tests: bone metastasis, metastasis of the lymph nodes,
visceral metastasis, CNS affection, hormone-receptor status,
Her2-status, menopausal status and primary metastasis. An
univariate Cox regression was performed to investigate the
influence of the following quantitative or semi-quantitativevariables: Charlson Score, age at initial diagnosis of metasta-
sis, time between diagnosis of breast cancer and metastasis
in months and number of metastatic sites. An adjustment
for multiple testing was applied.
All parameters that were found to be influential in the
univariate analyzes were tested in a multifactorial Cox
regression. The following parameters were included in a
forward stepwise modeling process: hormone-receptor
status, CNS affection, visceral localizations, age at initial
diagnosis of metastasis, time between diagnosis of breast
cancer and metastasis in months and number of meta-
static sites.
To evaluate a development of survival over time,
roughly equal quartiles of the diagnosis periods were
generated: before 2000, 01/2000-12/2003, 01/2004-12/
2007, 01/2008-06/2013. For these quartiles, median overall
and disease-specific survival was calculated and tested for
statistical significance.
All patients gave written informed consent concerning
analysis and publication of data.
Results
Patient characteristics
716 female patients were treated between 06/1995-06/
2013 (see Table 1). Median age at diagnosis of metastasis
was 61 years (31–93), 80% (n = 572) were postmenopausal.
Patients suffered from few comorbidities, mean Charlson
Score was 0.3 (0–5). Localizations of metastases were dis-
tributed as follows: 47% (n = 335) visceral, 36% (n = 256)
bone, 9% (n = 66) lymph nodes, 4% (n = 29) CNS and 4%
(n = 29) others. The mean number of involved organs was
1.4 (1–4). 79% of patients (n = 563) were hormone-
receptor-positive, 20% (n = 145) Her2-positive and 9%
(n = 62) triple-negative. In 7% of patients (n = 47) the
receptor status could not be determined retrospectively.
Palliative therapy
98% of patients (n = 701) received palliative therapy, 2%
(n = 15) solely best supportive care. A total of 3,346 pal-
liative therapies were carried out, the median number of
different lines per patient was 4 (0–20). First line therapy
consisted of endocrine treatment in 58% (n = 414). Agents
used were aromatase inhibitors in 74% (n = 308) and
tamoxifen in 21% (n = 88). First line therapy was chemo-
therapy in 40% (n = 284). Agents most frequently used were
anthracyclines in 29% (n = 82), taxanes in 24% (n = 68),
capecitabine in 14% (n = 40) and anthracycline/taxane-
combinations in 11% (n = 31).
Antihormonal therapies
86% (n = 484) of patients with hormone-receptor-positive
tumors (n = 563) received an antihormonal therapy in the
course of their disease. 89% (n = 429) of them received
an aromatase inhibitor, 37% (n = 181) fulvestrant, 28%
Table 1 Patient characteristics
Adjuvant therapy [multiple responses
possible]
- chemotherapy 42% n = 303
- antihormonal therapy 45% n = 320
- radiation 47% n = 333
Disease free survival from initial
diagnosis of breast cancer to
metastasis
- median 32.5 months
- < 24 months 42% n = 303
-≥ 24 months 58% n = 413
Age at diagnosis of
metastasis
- median 61 years
- < 50 years 20% n = 146
- 50–70 years 56% n = 402
- >70 years 23% n = 168
Menopausal status at time of
metastasis
- premenopausal 19% n = 134
- postmenopausal 80% n = 572
- not evaluable 1% n = 10
Hormone-receptor status
- negative 16% n = 117
- positive 79% n = 563
- not evaluable 5% n = 36
Her2 status
- negative 52% n = 369
- positive 20% n = 145
- not evaluable 28% n = 202
Comorbidities at time of
metastasis
- Charlson Score 0 81% n = 578
- Charlson Score 1 + 2 17% n = 123
- Charlson Score >2 2% n = 13
Metastatic status at initial
diagnosis of breast cancer
- M1 21% n = 151
- M0 76% n = 547
- not evaluable 3% n = 18
Localizations of metastases at
initial diagnosis of metastasis
- visceral 47% n = 335
- bone 36% n = 256
- CNS 4% n = 29
- lymph nodes 9% n = 66
- others 4% n = 29
Table 1 Patient characteristics (Continued)
Number of involved organs at
initial diagnosis of metastasis
- 1 localization 69% n = 493
- >1 localizations 31% n = 223
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3% (n = 14) everolimus.
Anti-Her2 therapies
81% (n = 118) of all Her2-positive patients (n = 145) re-
ceived an anti-Her2 therapy in the course of the disease.
98% (n = 116) of them were treated with trastuzumab,
23% (n = 27) with lapatinib, 6% (n = 7) with TDM-1 and
2% (n = 2) with trastuzumab + pertuzumab.
Chemotherapy and bevacizumab
83% of patients (n = 594) received at least one chemotherapy
line (0–17). Most frequently applied were anthracyclines
(mitoxantrone or epirubicin or doxorubicin) in 64% (n =
381), taxanes (58%, n = 346), capecitabine (54%, n = 323)
and vinorelbine (43%, n = 257). 16% (n = 93) were treated
with bevacizumab.
Bone protecting therapy
87% (n = 412) of patients with bone metastases (n = 475)
were treated with a bone protecting therapy. 94% (n =
388) of them received a bisphosphonate, 5% (n = 22) the
monoclonal RANK ligand inhibitor denosumab. The rate
of treatment-associated osteonecrosis of the jaw was 4%
(n = 16).
Treatment of brain metastases
At the time of diagnosis of metastasis 3% (n = 25) already
had one or more brain metastases. In the course of the
disease 18% (n = 132) of the patients developed brain
metastases. The treatment of brain metastases consisted
of whole brain radiation in 73% (n = 96), surgical resection
of metastases in 16% (n = 21) and intrathecal MTX therapy
in 5% (n = 7). In 17% of patients (n = 23) no therapy of
brain metastases was performed.
Toxicities and hospitalizations
Overall, grade 3 and grade 4 toxicities were low at 12%
of all 3,346 therapies. No treatment-associated death was
observed. After diagnosis of metastasis 82% (n = 584) of
patients had to be hospitalized during treatment. For all
patients the median frequency of hospitalizations was 2
(0–18), the median duration per hospital stay was 8 days
(1–79). The median cumulative duration of hospitalization
in an acute care hospital was 18 days (1–173). The median
duration of the last hospitalization before death was 6 days
(1–57). 71% (n = 508) of patients had to be hospitalized
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and only 6% (n = 40) due to side effects of palliative therapy.
Causes and places of death
At the end of the evaluation period (06/2013) 77% (n =
549) of patients had died. 37% (n = 202) were able to die
at home, 42% (n = 228) died in hospital, 6% (n = 31) in
nursing homes, 5% (n = 26) in hospice care. For 11%
(n = 62) the place of death could not be determined.
82% (n = 451) of the patients died of their tumor, 8%
(n = 46) of comorbidities. For 9% (n = 52) the cause of
death could not be determined. Treatment-related deaths
were not observed.
Survival
Median survival of all patients from initial diagnosis of
metastasis was 34 months (95% Confidence Interval
[CI]: 31–37), disease-specific survival was 36.8 months.
The disease-specific survival after 5 years was 34%, 12%
after 10 years and 6% after 15 years.
Significant differences (p < 0.01) in overall survival were
observed depending on localizations of metastases at ini-
tial diagnosis. Patients with lymph node metastases lived
47 months (95% CI: 36–58) in median, patients with solely
bone metastases 43 months (95% CI: 36–50), patients with
visceral metastases 26 months (95% CI: 23–29) and pa-
tients with CNS metastases only 11 months (95% CI: 0–
23). A significant survival difference could also be found
depending on the receptor status (p < 0.01). Patients with
hormone-receptor-positive tumors survived 37 months (95%
CI: 33–41) in median, Her2-positive patients 34 months
(95% CI: 27–41), triple-negative patients only 13 months
(95% CI: 6–20) (see Figure 1). No significant survival
difference was observed between patients with primary
metastases and patients whose metastases had occurred
after adjuvant therapy.
Median disease-specific survival as a function of diag-
nosis period was as follows: 32.7 months (before 2000),
36.9 months (01/2000-12/2003), 39.1 months (01/2004-
12/2007) and 34.5 months (01/2008-06/2013). Differences
in survival did not reach statistical significance. More than
90% of patients who were diagnosed before 12/2003 had
died, 78% in the diagnosis period 01/2004-12/2007 and
46% in the last cohort.
As significant in terms of survival proved in the multi-
variate approach the following parameters: CNS metastases,
positive hormone-receptor status, age at initial diagnosis of
metastasis, time between initial diagnosis of breast cancer
and metastasis in months and number of metastatic locali-
zations. The presence of CNS metastases had the strongest
impact on survival, whereas the presence of visceral metas-
tases failed to reach statistical significance. For patients with
CNS metastases the risk of dying was higher by 148% in
comparison to patients without CNS metastases. Of highpredictive value was also the hormone-receptor status.
Patients with a positive hormone-receptor status had a
40% lower risk of dying than patients with a negative
status. For the number of metastatic localizations could
be established that the risk of death for each additional
localization increased by 18%. The age at the time of
metastasis and the time between initial diagnosis of
breast cancer and metastasis had a small, albeit statis-
tically significant influence on survival. The longer the
time between initial diagnosis of breast cancer and
metastasis was, the longer the survival from metastasis,
namely 0.4% per month (see Table 2).
Discussion
Treatment goals of women with metastatic breast cancer
are prolongation of life and preservation of quality of life.
Prolongation of life
Median survival of patients with metastatic breast cancer
is 20–28 months (Mauri et al. 2008; Gennari et al. 2005;
Giordano et al. 2004; Chia et al. 2007; Tai et al. 2004;
Dafni et al. 2010; Tevaarwerk et al. 2013; Allemani et al.
2013) from diagnosis of metastasis. Disease-specific survival
after 5 years in breast cancer registries is 13% in England,
20-27% in Germany and 23-24% in the USA (Tumorregister
München http://www.tumorregister-muenchen.de/facts/surv/
surv_C50f_G.pdf; Holleczek et al. 2011; Weide et al. 2012;
Office for National Statistics (ONS) http://www.ons.gov.uk/
ons/publications/re-reference-tables.html?edition=tcm%3A77-
241176; Surveillance, Epidemiology and End Results Program
(SEER 18, 2004–2010) http://seer.cancer.gov/statfacts/html/
breast.html#survival). The survival of patients in prospective
clinical trials is very different due to necessary selection
criteria and different research objectives. We also know
that only about 2% of patients who are older than 60 are
treated within clinical trials (American College of Physi-
cians (ACP) http://www.acponline.org/products_services/
mksap/16/). Therefore, comparisons between study results
and routine care are very limited. Recent reports from the
Munich cancer registry (Schlesinger-Raab et al. 2005) and
the tumor registry of the Saarland (Holleczek et al. 2011)
show no improvement in survival in patients with meta-
static breast cancer in the last 20–30 years. In contrast,
there are a variety of publications from individual institu-
tions and tumor registries that describe a prolongation of
survival time in the last 20–30 years (Mauri et al. 2008;
Gennari et al. 2005; Giordano et al. 2004; Chia et al. 2007;
Tai et al. 2004; Dafni et al. 2010; Allemani et al. 2013;
Weide et al. 2009). Our analysis of more than 700 un-
selected, consecutive patients in routine care confirms a
prolongation of survival with a median overall survival of
34 months, a disease-specific survival of 36.8 months and
a disease-specific survival of 34% after 5 years. This
comparatively long survival in our population, however,
Figure 1 Overall survival depending on the receptor status.
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positive tumors most likely due to targeted therapies
directed against the estrogen-receptor and Her2.
Hormone-receptor-positive tumors
The current guidelines recommend for hormone-receptor-
positive tumors an antihormonal first-line therapy, if so
permitted by the clinical situation (Arbeitsgemeinschaft
Gynäkologische Onkologie (AGO) http://www.ago-online.
de/de/fuer-mediziner/leitlinien/mamma/; Onkopedia https://
www.dgho-onkopedia.de/de/mein-onkopedia/leitlinien/
brustkrebs-der-frau). In prospective clinical trials it
could be demonstrated that aromatase inhibitors are more
effective than tamoxifen in the antihormonal first-line
treatment of metastatic breast cancer in postmenopausal
patients (Nabholtz et al. 2000; Mouridsen et al. 2003). The
introduction of the new antiestrogen fulvestrant demon-
strated superiority to the aromatase inhibitor anastrozole
(Robertson et al. 2012). In a recent study, the superiority
of a combination of fulvestrant plus anastrozole compared
to a sole anastrozole therapy could be shown (Mehta et al.
2012).Table 2 Results of the Cox regression
Significance
Hormone-receptor status positive p < 0.001
CNS metastases p < 0.001
Age at initial diagnosis of metastasis [years] p < 0.001
Time [months] between initial diagnosis and metastasis p < 0.001
Number of metastatic localizations p = 0.010After resistance to a nonsteroidal aromatase inhibitor,
the combination of the steroidal aromatase inhibitor exe-
mestane plus the mTOR inhibitor everolimus showed a
significantly prolonged progression-free survival compared
with exemestane alone (Baselga et al. 2012). A meaningful
sequence in postmenopausal patients is the first-line
therapy with a nonsteroidal aromatase inhibitor, followed
by second-line treatment with fulvestrant, followed by
third-line therapy with the steroidal aromatase inhibitor
exemestane plus everolimus. If it is permitted by the
clinical situation patients should only then, in fourth line,
be treated with a chemotherapy.
Premenopausal patients should always be treated in first
line with an inhibition of ovarian function (LHRH agonist)
and tamoxifen or with an oophorectomy and an aromatase
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inhibitor, 37% (n = 181) with fulvestrant, 28% (n = 135)
with tamoxifen, 12% (n = 56) with a LHRH agonist and
3% (n = 14) with exemestane plus everolimus. In our
cohort the combination of exemestane plus everolimus
can't be made responsible for a prolongation of survival
because this combination was licensed in Germany just
a couple of months ago. Hormone-receptor-positive pa-
tients had a median overall survival of 37 months. Thus
our results imply most likely that the sequential use of
the most potent antihormonal therapies is the basis for
long-term survival in hormone-receptor-positive tumors
in routine care.
Her2-positive tumors
Her2-positive tumors are characterized by increased pro-
liferation, invasiveness and metastasis tendency (Slamon
et al. 1987). The median survival in Her2-positive tumors
is without anti-Her2 therapy only 18 months (Slamon et al.
1987; Marty et al. 2005). The monoclonal anti-Her2 anti-
body trastuzumab led with paclitaxel or anthracycline
chemotherapy to a prolongation of survival from 20.3 to
25.1 months (Slamon et al. 2001). Even in progressive
course under paclitaxel plus trastuzumab, it is useful to
maintain trastuzumab and convert only the chemotherapy
partner to a non-cross-resistant substance (von Minckwitz
et al. 2009). An alternative in tumor progression on trastu-
zumab offers the tyrosine kinase inhibitor lapatinib, which
is approved in Germany in combination with capecitabine
for this indication. Lapatinib has the advantage that it is
effective even in brain metastases due to its ability to pass
into the liquor (Lin et al. 2008). Recently the dual Her2
blockade with lapatinib and trastuzumab for patients suf-
fering from metastatic Her2-positive, hormone-receptor-
negative breast cancer was approved. A further develop-
ment is the new anti-Her2 antibody pertuzumab which
prevents the heterodimerization between Her2 and Her3.
Thus the intracellular tyrosine kinase is not activated, which
is responsible for the initiation of the activation cascade.
In the CLEOPATRA-trial it could be proved that the
dual inhibition of Her2 by trastuzumab and pertuzumab
in combination with docetaxel chemotherapy prolonged
survival significantly compared with the combination of
docetaxel plus trastuzumab (Swain et al. 2013). Another
new development is the anti-Her2 antibody TDM-1, where
emtansine, a highly effective microtubule inhibitor, is
coupled with trastuzumab. Through the internalization
of Her2 plus TDM-1 emtansine enters the Her2-positive
cell and can induce a selective cell death. In the EMILIA
trial it could be demonstrated that TDM-1 is more effect-
ive than lapatinib plus capecitabine in tumor progression
on a trastuzumab-containing regimen (Verma et al. 2012).
In our collective 20% (n = 145) of patients suffered from
Her2-positive tumors. In the course of treatment 81%(n = 118) of these patients received an anti-Her2 therapy
(98% (n = 116) trastuzumab, 23% (n = 27) lapatinib, 6%
(n = 7) TDM-1 and 2% (n = 2) trastuzumab + pertuzumab)).
In our analysis pertuzumab and TDM-1 can't be made re-
sponsible for a prolongation of survival because they were
licensed in Germany as recently as 2013. The overall sur-
vival of Her2-positive patients was 34 months and thus em-
phasizes the importance of a targeted anti-Her2 therapy in
routine care of patients with metastatic breast cancer.
Triple-negative tumors
9% of patients (n = 62) suffered from a tumor which
was neither hormone-receptor- nor Her2-positive. Triple-
negative tumors are characterized by a very aggressive
course and a high metastatic tendency. In studies, the
median survival is only 9–11 months (Carey et al. 2012).
In our collective, the median survival was only 13 months,
well below that of the hormone-receptor- or Her2-positive
tumors. Neoadjuvant studies presented at the San Antonio
Breast Cancer Symposium 2013 suggest that treatments
using carboplatin and PARP-inhibitors like veliparib may
be especially effective in triple negative tumors (Sikov et al.
2013; Rugo et al. 2013). These treatments may be used
successfully in the metastatic situation as well.
Preservation of quality of life
The preservation of quality of life is the second major
goal in the treatment of patients with metastatic breast
cancer. The concept of an oncology group practice makes
it possible to treat patients close to residence at a high
professional level. It seems important to us to point out in
this connection the continuity and constancy of care of
patients and their relatives by the oncology team. In an
own analysis we found a mean psychosocial distress level
of only 5.2 for patients with metastatic breast cancer who
were treated in our practice (Mergenthaler et al. 2011).
This value was determined in a cross-sectional survey
using the NCCN Distress Thermometer. Another import-
ant factor for holistic care is in our opinion the double
qualification as medical oncologist and palliative care
physician since throughout the course of the disease, with
varying intensity, always palliative care aspects come to
the fore.
The strengths of this evaluation are the high number
of patients treated over 18 years, the completeness of
treatment data and the fact that no patients were excluded
from the analysis. Potential drawbacks of the study are
that this is a retrospective unicenter analysis and that we
have no standardized data concerning best response and
progression-free-survival.
Conclusion
In conclusion, the treatment of unselected patients with
metastatic breast cancer in an oncology group practice
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try data from Germany, England and the United States.
Prolongation of survival was restricted to patients with
hormone-receptor- and Her2-positive tumors most likely
due to targeted therapies directed against the estrogen re-
ceptor and Her2.
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